Repligen Corp. (RGEN) Company Profile & Statistics

Repligen Corp.
RGEN
(Nasdaq - US)
N/A
165.44
-2.42 (-1.44%)
in:usd•As of: Apr 25, 2024 11:42 UTC -4
Open
167.29
High
169.93
Low
163.40

About Repligen Corp.

CEO

Tony J. Hunt

Headquarters

41 seyon street, building 1, suite 100

waltham, ma 02453, united states

Auditor

Ernst & Young LLP

Employees

1,783

Share Holders

259

Website

www.repligen.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.

Repligen Corp. Statistics

Valuation Measures

Market Capitalization ²	9.24B
Enterprise Value	9.07B
Enterprise Value/EBITDA (ttm)	72.47
Price to Earnings Ratio (ttm)	99.01
Price to Book (mrq)	4.85
Price to Sales (ttm)	14.97
Price to Cash (ytd)	56.61

Profitability

Gross Margin (ttm)	43.67%
Operating Margin (ttm)	15.40%
Profit Margin (ttm)	6.22%
Return on Equity (ttm)	5.00%
Return on Invested Capital (ttm)	2.39%
Return on Assets (ttm)	3.78%

Income Statement

Revenue (ttm)	638.76M
Revenue Per Share (ttm)	11.45
Gross Profit (ttm)	284.84M
EBITDA (ttm)³	125.11M
Net Income Avi to Common (ttm)	41.58M
Diluted EPS (ttm)	0.72

Share Statistics

Beta (5Y Monthly)	1.02
52-Week Change	10.63%
S&P500 52-Week Change	23.10%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	55.77M
Dividend Yield	0.00%
Float ⁴	55.17M
% Held by Insiders	1.20%
% Held by Institutions	97.64%

Balance Sheet

Total Cash (mrq)	751.32M
Total Cash Per Share (mrq)	13.47
Total Debt (mrq)	579.60M
Total Debt/Equity (mrq)	29.40%
Current Ratio (mrq)	7.02%
Quick Ratio (mrq)	5.75%
Book Value Per Share (mrq)	35.35

Cash Flow

Operating Cash Flow Per Share (ytd)	2.02
Free Cash Flow (ytd)	74.93M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Repligen Corp.

Trade With A Regulated Broker